摘要
目的：针对头孢哌酮/舒巴坦致血小板减少开展信息化主动监测,并评价系统升级版的功能。方法：采用回顾性分析方法,利用＂医疗机构ADE主动监测与智能评估警示系统＂对2014年7~12月使用目标药物的住院患者进行主动监测,对系统报警病例进行人工甄别,并对版本升级前后监测数据结果进行分析比较。结果：注射用头孢哌酮/舒巴坦导致血小板减少ADE发生率为3.00%,远高于说明书中所列的0.08%;不同版本的主动监测报警阳性率在26.00%~46.67%之间。升级版主动监测系统的报警阳性率由旧版的26.00%提升为35.00%,排除字段补充后报警阳性率更进一步上升为46.67%。结论：升级版系统软件的主动监测效果优化显著,能够为药品安全性监测提供更加高效、快捷的辅助工具,得到的ADR/ADE发生率更加反映临床用药人群的真实情况。
Objective： To investigate the cefoperazone/sulbactam-induced thrombecytopenia, a upgraded version of intelligence assessment warning system for ADE was applied to do active monitoring, and its function was evaluated. Methods：The retrospective analysis was used to do active monitoring on inpatients who had target drugs during July 1 st, 2014 to December 31st, 2014 detecting by the intelligence assessment warning system for ADE. We manual screened the cases which selected by system, and analyzed monitoring data before and after the upgrade. Results： The ADE rate of thrombocytopenia was 3.00% in cefoperazone sodium sulbaetarn group, that was much higher than O. 08% listed in the in- struction manual; Alarm positive rate was between 26.00%-46.67% in different versions of the active monitoring. And the alarm positive rate was increased to 35% in the upgrade system compared the 26.00% in the old version system. Further- more, it increased to 46.67% after excluding the complement. Conclusion：The active monitoring was optimized significant- ly by using upgraded version of system. And this new version of software was a more efficient and speedy aid to drug safety monitoring. Besides, it reflected the true ADR/ADE rate of patients with clinical medicine.
出处
《药物流行病学杂志》
CAS
2016年第1期17-20,共4页
Chinese Journal of Pharmacoepidemiology
基金
2014年全军后勤科研重点项目(编号:BWS14R039)
